Early Access – PIM and EAMS
Executive Summary
- PIM and EAMS provide early access to medicines that are not yet available as licensed treatments access for seriously debilitating or life-threatening conditions
- It is a two-step process:
- PIM designation – valid indefinitely
- EAMS scientific opinion – valid for one year but can be renewed
- This section guides you through the application process, with downloadable templates to facilitate your submission, and highlights the advantages and disadvantages of obtaining a PIM and/or EAMS on your overall market access strategy
Membership required to access MAP Online
Benefits of a membership to MAP Online include:
- Access to up-to-date, validated and detailed market access guides
- Downloadable tools, slide decks, flowcharts and more...
- Free workshops with every new membership to help you get the most out of MAP
MAP UK - Table of Contents
